retatrutide clinical trial results weight loss efficacy Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care π¨ TRIUMPH-1: #retatrutide topline dataπ¨
Description
In cultured human islets and in C57BL/6 mice, both aGLP1 and aGLP1-E2 enhanced glucose-stimulated insulin secretion (GSIS) compared to vehicle and iGLP1-E2 without superior efficacy of aGLP1-E2 compared to GLP-1 alone
[DOI] [PMC free article] [PubMed] [Google Scholar] 35.Taruno A, Vingtdeux V, Ohmoto M, Ma Z, Dvoryanchikov G, Li A, Adrien L, Zhao H, Leung S, Abernethy M, Koppel J, Davies P, Civan MM, Chaudhari N, Matsumoto I, Hellekant G, Tordoff MG, Marambaud P, Foskett JK
Overall the research confirmed an old observation that oral and intravenous glucose prompted different physiological responses (Marks, Samols)
Finally, research from March 2025 indicates that undertaking regular moderate-to-vigorous exercise could help lower the risk for neuropsychiatric diseases, including depression
SGLT2is, and GLP-1 RAs in particular promote weight loss, and therefore especially may be of benefit, given that overweight and obesity is increasingly prevalent (62%) in individuals with type 1 diabetes [12]
Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice
